Pharma QMS Market to Hit $4.64 Billion by 2034 as AI and Compliance Demands Lift Growth
Updated
Updated · Fortune Business Insights · Aug 13
Pharma QMS Market to Hit $4.64 Billion by 2034 as AI and Compliance Demands Lift Growth
1 articles · Updated · Fortune Business Insights · Aug 13
Summary
$1.59 billion in 2026 revenue is forecast to climb to $4.64 billion by 2034, implying a 14.24% CAGR for pharma quality management software.
Stricter GxP, data-integrity and inspection-readiness requirements are pushing drugmakers, biotechs and outsourcing partners to replace paper-based and legacy systems with validated cloud eQMS platforms.
AI is emerging as a key differentiator, helping vendors automate quality-event classification, summarize investigations and flag recurring deviations or compliance risks across CAPA, audits and change control.
Cloud-based SaaS led deployment in 2025 and is expected to hold 50.3% of the market in 2026, while integrated platforms remained the top product type and North America stayed the largest region.
High implementation, validation and data-migration costs still constrain adoption, especially for smaller companies, even as SMEs and emerging biotechs become a major expansion opportunity.